These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12414617)

  • 41. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.
    Mazzacurati L; Pattacini L; Brusa G; Mancini M; Benvenuti M; Barbieri E; Martinelli G; Baccarani M; Greenberger JS; Santucci MA
    Hematol J; 2004; 5(2):168-77. PubMed ID: 15048068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate.
    Leguay T; Desplat V; Lagarde V; Marit G; Reiffers J; Mahon FX
    Leukemia; 2005 Sep; 19(9):1671-3. PubMed ID: 15973458
    [No Abstract]   [Full Text] [Related]  

  • 44. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
    Hofmann WK; Jones LC; Lemp NA; de Vos S; Gschaidmeier H; Hoelzer D; Ottmann OG; Koeffler HP
    Blood; 2002 Mar; 99(5):1860-2. PubMed ID: 11861307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer research. Why some leukemia cells resist STI-571.
    Marx J
    Science; 2001 Jun; 292(5525):2231-3. PubMed ID: 11423629
    [No Abstract]   [Full Text] [Related]  

  • 46. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.
    Miething C; Feihl S; Mugler C; Grundler R; von Bubnoff N; Lordick F; Peschel C; Duyster J
    Leukemia; 2006 Apr; 20(4):650-7. PubMed ID: 16482207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
    Kancha RK; von Bubnoff N; Miething C; Peschel C; Götze KS; Duyster J
    Haematologica; 2008 Nov; 93(11):1718-22. PubMed ID: 18728023
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
    Hofmann WK; Komor M; Wassmann B; Jones LC; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG
    Blood; 2003 Jul; 102(2):659-61. PubMed ID: 12663457
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.
    Cowan-Jacob SW; Guez V; Fendrich G; Griffin JD; Fabbro D; Furet P; Liebetanz J; Mestan J; Manley PW
    Mini Rev Med Chem; 2004 Mar; 4(3):285-99. PubMed ID: 15032675
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [STI571: the resistance organizes!].
    Jeanteur P
    Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306
    [No Abstract]   [Full Text] [Related]  

  • 51. ARG tyrosine kinase activity is inhibited by STI571.
    Okuda K; Weisberg E; Gilliland DG; Griffin JD
    Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
    Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
    Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
    Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC
    J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.
    Branford S; Rudzki Z; Walsh S; Grigg A; Arthur C; Taylor K; Herrmann R; Lynch KP; Hughes TP
    Blood; 2002 May; 99(9):3472-5. PubMed ID: 11964322
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia.
    Press RD
    Mol Diagn; 2001 Sep; 6(3):211-3. PubMed ID: 11571715
    [No Abstract]   [Full Text] [Related]  

  • 56. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
    Carter BZ; Mak DH; Schober WD; Cabreira-Hansen M; Beran M; McQueen T; Chen W; Andreeff M
    Blood; 2006 Feb; 107(4):1555-63. PubMed ID: 16254145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tyrosine kinase inhibitor STI571 (Imatinib) cooperates with wild-type p53 on K562 cell line to enhance its proapoptotic effects.
    Brusa G; Mancini M; Campanini F; Calabrò A; Zuffa E; Barbieri E; Santucci MA
    Acta Haematol; 2005; 114(3):150-4. PubMed ID: 16227678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents.
    Liu WM; Stimson LA; Joel SP
    Br J Cancer; 2002 May; 86(9):1472-8. PubMed ID: 11986783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia.
    Wang W; Du Y; Li NN; Lv FF; Lin GQ
    Genet Mol Res; 2014 May; 13(2):4089-101. PubMed ID: 24938701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
    Weisberg E; Griffin JD
    Blood; 2000 Jun; 95(11):3498-505. PubMed ID: 10828035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.